Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Typical Teratoid Rhabdoid Tumor 1Pinealoma 1Paraganglioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma 1Choroid Plexus Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 3Temozolomide 3Specimen Handling 3Radiotherapy 2peposertib 1liposomal doxorubicin 1gosha-jinki-gan 1efineptakin alfa 1cabozantinib 1balstilimab 1atezolizumab 1abexinostat 1Surgical Procedures, Operative 1Radiation 1ONC206 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gliosarcoma × ONC206 × Clear all
NCT04541082 2025-12-18

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Jazz Pharmaceuticals

Phase 1 Recruiting
102 enrolled
CNSSarcoma

Typical Teratoid Rhabdoid Tumor, Astrocytoma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Oligodendroglioma, Pinealoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡